ATE478678T1 - Behandlung von amyotrohper lateralsklerose - Google Patents

Behandlung von amyotrohper lateralsklerose

Info

Publication number
ATE478678T1
ATE478678T1 AT05747975T AT05747975T ATE478678T1 AT E478678 T1 ATE478678 T1 AT E478678T1 AT 05747975 T AT05747975 T AT 05747975T AT 05747975 T AT05747975 T AT 05747975T AT E478678 T1 ATE478678 T1 AT E478678T1
Authority
AT
Austria
Prior art keywords
treatment
lateral sclerosis
amyotrohper
relates
als
Prior art date
Application number
AT05747975T
Other languages
English (en)
Inventor
Peter Carmeliet
Original Assignee
Vib Vzw
Life Sciences Res Partners Vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vib Vzw, Life Sciences Res Partners Vzw filed Critical Vib Vzw
Application granted granted Critical
Publication of ATE478678T1 publication Critical patent/ATE478678T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Automatic Cycles, And Cycles In General (AREA)
AT05747975T 2004-05-27 2005-05-27 Behandlung von amyotrohper lateralsklerose ATE478678T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04102334 2004-05-27
PCT/EP2005/052430 WO2005117946A1 (en) 2004-05-27 2005-05-27 Treatment of amyotrophic lateral sclerosis

Publications (1)

Publication Number Publication Date
ATE478678T1 true ATE478678T1 (de) 2010-09-15

Family

ID=34968798

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05747975T ATE478678T1 (de) 2004-05-27 2005-05-27 Behandlung von amyotrohper lateralsklerose

Country Status (17)

Country Link
US (2) US7687463B2 (de)
EP (1) EP1755647B1 (de)
JP (2) JP5537770B2 (de)
AT (1) ATE478678T1 (de)
AU (1) AU2005249234B2 (de)
CA (1) CA2568158A1 (de)
CY (1) CY1111654T1 (de)
DE (1) DE602005023155D1 (de)
DK (1) DK1755647T3 (de)
ES (1) ES2351804T3 (de)
HR (1) HRP20100555T1 (de)
ME (1) ME01870B (de)
PL (1) PL1755647T3 (de)
PT (1) PT1755647E (de)
RS (1) RS51481B (de)
SI (1) SI1755647T1 (de)
WO (1) WO2005117946A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE526981T1 (de) * 2000-04-12 2011-10-15 Vib Vzw Verwendung von vegf 165 und homologen zur behandlung von neurologischen störungen
PL1755647T3 (pl) * 2004-05-27 2011-01-31 Vib Vzw Leczenie stwardnienia zanikowego bocznego
WO2012048330A2 (en) * 2010-10-08 2012-04-12 The Mclean Hospital Corporation Treatment of motor neuron disease
EP2882429B1 (de) * 2012-08-07 2024-04-10 The General Hospital Corporation Kaliumkanal-Öffner zur Verwendung bei der Behandlung der amyotrophen Lateralsklerose (ALS)
US20140155816A1 (en) * 2012-10-09 2014-06-05 Eu Sol Biotech Co., Ltd. Method for treating brain injury or stroke
ES2796853T3 (es) * 2013-10-01 2020-11-30 Kadimastem Ltd Diferenciación dirigida de astrocitos a partir de células madre pluripotentes humanas para uso en el cribado de medicamentos y el tratamiento de la esclerosis lateral amiotrófica (ELA)
KR20230138815A (ko) * 2022-03-24 2023-10-05 주식회사 아이엔테라퓨틱스 인비보 패치 클램프 기법을 이용한 전기생리학적 약효 평가법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
WO2004031390A1 (en) * 2002-10-04 2004-04-15 Oxford Biomedica (Uk) Limited Vector system
WO1998031395A1 (en) 1997-01-17 1998-07-23 Rhone-Poulenc Rorer S.A. Adenoviral-vector-mediated gene transfer into medullary motor neurons
CA2322748A1 (en) 1998-03-13 1999-09-16 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
JP4532733B2 (ja) 1998-03-17 2010-08-25 ジェネンテック， インコーポレイテッド Ｖｅｇｆおよびｂｍｐ１と相同なポリペプチド群
WO2000017371A1 (en) 1998-09-23 2000-03-30 Oxford Biomedica (Uk) Limited Polynucleotide constructs and uses thereof
US7125856B1 (en) 1999-04-15 2006-10-24 St. Elizabeth's Medical Center Of Boston, Inc. Angiogenic growth factors for treatment of peripheral neuropathy
CA2365434A1 (en) 1999-04-15 2000-10-26 St. Elizabeth's Medical Center Of Boston Angiogenic growth factors for treatment of peripheral neuropathy
ATE526981T1 (de) 2000-04-12 2011-10-15 Vib Vzw Verwendung von vegf 165 und homologen zur behandlung von neurologischen störungen
US7981863B2 (en) * 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
PL1755647T3 (pl) * 2004-05-27 2011-01-31 Vib Vzw Leczenie stwardnienia zanikowego bocznego

Also Published As

Publication number Publication date
CY1111654T1 (el) 2015-10-07
ES2351804T3 (es) 2011-02-10
HRP20100555T1 (hr) 2011-01-31
WO2005117946A1 (en) 2005-12-15
RS51481B (en) 2011-04-30
PL1755647T3 (pl) 2011-01-31
JP2012111774A (ja) 2012-06-14
US20100152116A1 (en) 2010-06-17
EP1755647A1 (de) 2007-02-28
PT1755647E (pt) 2010-09-29
EP1755647B1 (de) 2010-08-25
SI1755647T1 (sl) 2011-01-31
DE602005023155D1 (de) 2010-10-07
US20080279906A1 (en) 2008-11-13
DK1755647T3 (da) 2010-10-11
CA2568158A1 (en) 2005-12-15
US7687463B2 (en) 2010-03-30
AU2005249234A1 (en) 2005-12-15
JP5537770B2 (ja) 2014-07-02
JP2008500312A (ja) 2008-01-10
AU2005249234B2 (en) 2010-08-05
ME01870B (me) 2011-04-30
US7863246B2 (en) 2011-01-04

Similar Documents

Publication Publication Date Title
CY1111654T1 (el) Θεραπευτικη αγωγη πλαγιας μυατροφικης σκληρυνσης
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
DOP2015000043A (es) Agentes inductores de apoptosis para el tratamiento de cáncer y enfermedades inmunes y autoinmunes
ATE489957T1 (de) Mittel zur behandlung von entzündlichen erkrankungen
ATE457989T1 (de) Bi- und trizyklische substituierte phenyl- methanone als inhibitoren von glycin-i (glyt-1)- transportern zur behandlung der alzheimer- krankheit
EA200501771A1 (ru) Лиганды каннабиноидных рецепторов и их применения
DE602004028763D1 (de) Te zur behandlung von virenerkrankungen
EA200700382A1 (ru) Фунгицидные композиции
DE602004022061D1 (de) Verwendung von modifizierten cyclosporinen zur behandlung von hcv-erkrankungen
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
ATE446102T1 (de) Behandlung von gewichtsverlust bei patienten mit entzündlichen darmerkrankungen mittels s. boulardii
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
ATE469657T1 (de) Immunstimulatorische kombination zur vorbeugung und behandlung von hepatitis c
ATE398398T1 (de) Nahrungsmittelzusatz
ATE526970T1 (de) Behandlung von mastitis
EA200600374A1 (ru) Замещённые пиперидинофенилоксазолидиноны, обладающие противомикробной активностью, с повышенной in vivo эффективностью
DE602005013650D1 (de) Proteinhydrolysat zur behandlung von müdigkeit
ATE482706T1 (de) Behandlung bakterieller erkrankungen der atmungsorgane durch lokale applikation von fluorchinolonen
ATE478707T1 (de) Kim-1-antikörper zur behandlung von th2- vermittelten erkrankungen
FR2867026B1 (fr) Composition phytosanitaire destinee au traitement antifongique des cultures.
ATE343387T1 (de) S-methyl-dihydro-ziprasidon zur behandlung von augenerkrankungen.
ATE545421T1 (de) Pharmazeutisches präparat zur behandlung von parasitären tropenkrankheiten enthaltend diminazen-di-aceturat
DE60330233D1 (de) Arsentherapie zur behandlung von autoimmunerkrankungen
ATE476185T1 (de) Verwendung von ciclesonid zur behandlung von entzündlichen darmerkrankungen
ATE433983T1 (de) Thiadibenzoazulenderivate zur behandlung von entzündlichen erkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1755647

Country of ref document: EP